Detalles de la búsqueda
1.
Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Invest New Drugs
; 38(5): 1463-1471, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32157599
2.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
N Engl J Med
; 367(12): 1087-97, 2012 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22992072
3.
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
Mult Scler
; 20(2): 253-7, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24150778
4.
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
Nat Med
; 13(2): 211-7, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17237795
5.
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.
J Immunol
; 183(6): 4067-76, 2009 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19687098
6.
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis.
Proc Natl Acad Sci U S A
; 105(48): 18889-94, 2008 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-19028871
7.
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.
J Exp Med
; 199(7): 971-9, 2004 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-15067033
8.
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells.
Brain
; 131(Pt 7): 1701-11, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18567923
9.
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
Alzheimers Dement (N Y)
; 5: 216-227, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31211217
10.
GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes.
J Clin Invest
; 109(7): 895-903, 2002 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-11927616
11.
Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.
Int J MS Care
; 18(3): 138-46, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27252601
12.
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
Clin Ther
; 37(7): 1402-1419.e5, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25999183
13.
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Clin Ther
; 37(11): 2543-51, 2015 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26526385
14.
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
Int J MS Care
; 17(5): 236-43, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26472945
15.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Neurol Ther
; 4(2): 93-104, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26662361
16.
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
Ann Clin Transl Neurol
; 2(2): 103-18, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25750916
17.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Neurology
; 84(11): 1145-52, 2015 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25681448
18.
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Clin Ther
; 36(12): 1958-1971, 2014 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25315404
19.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
J Neurol
; 260(4): 1136-46, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23263473
20.
Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].
Clin Ther
; 40(5): 812, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29523369